Company No: 11273835 (England and Wales)

Contents

• Balance Sheet
• Notes to the Financial Statements

		2026		2025
		£		£
Fixed assets		77,967		104,397
Current assets		3,758		43,469
Creditors: amounts falling due within one year		( 41,813)		( 84,414)
Net current liabilities		( 38,055)		( 40,945)
Total assets less current liabilities		39,912		63,452
Accruals and deferred income		( 3,050)		( 2,900)
Net assets		36,862		60,552
Capital and reserves		36,862		60,552

For the financial year ending 31 March 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
• The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements;
• These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime;
• These financial statements have been delivered in accordance with the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Novalio Pharma Limited (registered number: 11273835) were approved and authorised for issue by the director and were signed on its behalf by:

Dr. Anuj Madhok Director

06 October 2026

1. Company information

The Company is a private company limited by shares and is incorporated in the United Kingdom and registered in England and Wales (Company no. 11273835). The address of its registered office is First Floor, 5 Fleet Place, London, EC4M 7RD, United Kingdom.

2. Employees

	2026		2025
	Number		Number
Monthly average number of persons employed by the Company during the financial year, including the director	-		-